Cargando…
Understanding WT1 Alterations and Expression Profiles in Hematological Malignancies
SIMPLE SUMMARY: The transcription factor Wilms tumor one (WT1) is highly expressed in malignant cells of patients with hematological malignancies, with a considerable percentage of patients harboring deactivating mutations in this gene. To date, the extent of WT1’s contribution to leukemogenesis is...
Autores principales: | Niktoreh, Naghmeh, Weber, Lisa, Walter, Christiane, Karimifard, Mahshad, Hoffmeister, Lina Marie, Breiter, Hannah, Thivakaran, Aniththa, Soldierer, Maren, Drexler, Hans Günther, Schaal, Heiner, Sendker, Stephanie, Reinhardt, Dirk, Schneider, Markus, Hanenberg, Helmut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340278/ https://www.ncbi.nlm.nih.gov/pubmed/37444601 http://dx.doi.org/10.3390/cancers15133491 |
Ejemplares similares
-
Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022) -
Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia
por: Hoffmeister, Lina Marie, et al.
Publicado: (2021) -
Redirecting the Immune Microenvironment in Acute Myeloid Leukemia
por: Sendker, Stephanie, et al.
Publicado: (2021) -
Mutated WT1, FLT3-ITD, and NUP98-NSD1 Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia
por: Niktoreh, Naghmeh, et al.
Publicado: (2019) -
RUNX1 mutation has no prognostic significance in paediatric AML: a retrospective study of the AML-BFM study group
por: Sendker, Stephanie, et al.
Publicado: (2023)